Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 111,995 shares of the medical research company’s stock after purchasing an additional 3,714 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.22% of Charles River Laboratories International worth $22,060,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in CRL. Boston Trust Walden Corp raised its position in shares of Charles River Laboratories International by 2.8% in the 2nd quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock worth $41,381,000 after buying an additional 5,375 shares during the period. Natixis acquired a new stake in Charles River Laboratories International during the first quarter worth about $1,058,000. Tidal Investments LLC raised its holdings in shares of Charles River Laboratories International by 99.8% in the 1st quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company’s stock worth $1,435,000 after purchasing an additional 2,646 shares during the period. Epoch Investment Partners Inc. lifted its stake in shares of Charles River Laboratories International by 2,733.4% in the 1st quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock valued at $67,060,000 after purchasing an additional 238,766 shares in the last quarter. Finally, Quest Partners LLC grew its holdings in shares of Charles River Laboratories International by 135,175.0% during the 2nd quarter. Quest Partners LLC now owns 5,411 shares of the medical research company’s stock worth $1,118,000 after purchasing an additional 5,407 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. The Goldman Sachs Group reduced their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Robert W. Baird lowered their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. Bank of America lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their price objective for the company from $250.00 to $215.00 in a research report on Wednesday, October 2nd. Finally, UBS Group upped their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $217.54.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Down 4.7 %

CRL stock opened at $187.74 on Monday. The company has a market capitalization of $9.60 billion, a P/E ratio of 23.50, a PEG ratio of 4.84 and a beta of 1.38. The firm has a 50 day simple moving average of $195.26 and a 200-day simple moving average of $207.19. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the previous year, the firm earned $2.72 EPS. The company’s revenue was down 1.6% on a year-over-year basis. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its board has authorized a stock repurchase program on Wednesday, August 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 9.6% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).